Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 …

Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE…#primaryresults #incorporatedcytk #sequoiahcm #efficacy #phase3 #hcm #heartfailure #lisbon #portugal #martinmaron
Source: Reuters: Health - Category: Consumer Health News Source Type: news